

**BIBLIOGRAFIA**

## A

- Abrams J.** Interactions between organic nitrates and thiol groups. *Am J Med* . 1991;91:106S-112S.
- Aleryani S, Milo E, Rose Y, Kostka P.** Superoxide-mediated decomposition of biological S-nitrosothiols. *J Biol Chem*. 1998;273:6041-6045.
- Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V.** Angiographic evolution of coronary artery morphology in unstable angina. *J Am Coll Card*. 1988;12:56-62.
- Andreeva ER, Pugach IM, Orekhov AN.** Collagen-synthesizing cells in initial and advanced atherosclerotic lesions of human aorta *Atherosclerosis*. 1997;130:133-142.
- Antithrombotic Trialists' Collaboration.** Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324:71-86.

## B

- Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L.** Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques. *Circulation*. 1999;99:1780-1787.
- Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V.** Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. *Arteriosclerosis*. 1986;6:312-320.
- Badimon L, Turitto V, Rosemark JA, Badimon JJ, Fuster V.** Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. *J Lab Clin Med*. 1987;110:706-718. Erratum in: *J Lab Clin Med* 1988 ;111:5.
- Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V.** Platelet thrombus formation on collagen type I a model of deep vessel injury. Influence of blood rheology, von Willebran factor and blood coagulation. *Circulation* 1988;78:1431-1442
- Badimon L, Badimon JJ.** Mechanisms of arterial trombosis in non-parallel streamlines. Platelet thrombi grow on the apex of stenotic severely injured vessel. Experimental study in pig model. *J Clin Invest*. 1989;84:1134-1144.



- Badimon L, Chesebro JH, Badimon JJ.** Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. *Circulation*. 1992;86:III74-85
- Badimon L, Martínez-González J, Royo T, Lassila R, Badimon JJ.** A sudden increase in plasma epinephrine levels transiently enhances platelet deposition on severely damaged arterial wall. Studies in a porcine model. *Thromb Haemost* . 1999;82:1736-1742.
- Barnes CS, Krafft B, Frech M, Hofmann UR, Papendieck A, Dahlems U, Gellissen G, Hoylaerts MF.** Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen. *Semin Thromb Hemost*. 2001 ;27:337-348.
- Bastida E, Escolar G, Ordinas A, Sixma JJ.** Fibronectin is required for platelet adhesion and for thrombus formation on subendothelium and collagen surfaces. *Blood* 1987;70:1437-1442.
- Beckman JS, Koppenol WH.** Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. *Am J Physiol*. 1996;271:1424-1437.
- Begum N, Sandu OA, Duddy N.** Negative regulation of rho signaling by insulin and its impact on actin cytoskeleton organization in vascular smooth muscle cells: role of nitric oxide and cyclic guanosine monophosphate signaling pathways. *Diabetes*. 2002;51:2256-2263.
- Benjamin Z, James L, Satya P, Kunapuli S.** Platelet shape change is mediated by both calcium-dependent and-independent signalling pathways. *The Journal of Biological Chemistry* 1999;274:28293-28300.
- Bernassola F, Rossi A, Melino G.** Regulation of transglutaminases by nitric oxide. *Ann N Y Acad Sci*. 1999;887:83-91.
- Berndt MC, Ward CM, Booth WJ, Castaldi PA, Mazurov AV, Andrewss RK.** Identification of aspartic acid 514 through glutamic acid 542 as glycoprotein Ib-IX complex receptor recognition sequence in VWF. Mechanisms of modulation of VWF by ristocetin and botrocetin. *Biochemistry*. 1992;31:11144-11151.
- Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT.** Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). *Circulation*. 2000;102:624-629.

- Bobryshev YV, Lord RS, Warren BA.** Calcified deposit formation in intimal thickenings of the human aorta. *Atherosclerosis*. 1995;118:9-21.
- Bodie S, Ford I, Greaves M, Nixon GF.** Thrombin-induced activation of Rho-A in platelet shape change. *Biochemical and Biophysiological Research Communications*. 2001;287:71-76.
- Bodzenta-Lukaszyk A, Gabryelewicz A, Lukaszyk A, Bielawiec M, Konturek JW, Domschke W.** Nitric oxide synthase inhibition and platelet function. *Thromb Res*. 1994;75:667-672.
- Bossavy JP, Thalamas C, Sagnard L, Barret A, Sakariassen K, Boneu B, Cadroy Y.** A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. *Blood*. 1998;92:1518-1525.
- Boyle JJ, Bowyer DE, Weissberg PL, Bennett HR.** Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cell by fas-ligand/fas interactions. *Arterioscler Thromb Vasc Biol*. 2001;21:1402-1407.
- Braganza DM, Bennett MR.** New insights into atherosclerotic plaque rupture. *Postgrad Med J*. 2001;77:94-98
- Buga G. M, Griscavage J. M., Rogers N. E.** Negative feedback regulation of endothelial cell function by nitric oxide. *Circ. Res* 1993;73:808-812.
- Bürrig KF.** The endothelium of advanced atherosclerotic plaques in humans, *Arterioscler Thromb Vasc Biol*. 1991;11;1678-1689.

---

**C**

---

- Cable DG, O'Brien T, Kullo IJ, Schwartz RS, Schaff HV, Pompili VJ.** Expression and function of a recombinant endothelial nitric oxide synthase gene in porcine coronary arteries. *Cardiovasc Res*. 1997 Sep;35(3):553-9.
- Cadroy Y, Hanson SR, Kelly AB, Marzec UM, Evatt BL, Kunicki TJ, Montgomery RR, Harker LA.** Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. *Blood*. 1994; 83: 3218-24.
- Cai H, Harrison DG.** Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. *Circ Res*. 2000;87:840-844.
- Cambria-Kiely JA, Gandhi PJ.** Aspirin resistance and genetic polymorphisms. *J Thromb Thrombolysis*. 2002;14:51-58.



- Camejo G, Fager G, Rosengren B, Hurt-Camejo E, Bondjers G.** Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. *J Biol Chem.* 1993;268:14131-14137.
- CAPRIE Steering Committee.** A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet.* 1996;348:1329-1339.
- CAPTURE: Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML.** Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. *N Engl J Med.* 1999 ;340:1623-1629.
- CARE: Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol And Recurrent Events (CARE) Trial Investigators.** The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med.* 1996;335:1001-1009.
- Cauwenberghs N, Meiring M, Vauterin S, van Wyk V, Lamprecht S, Roodt JP, Novak L, Harsfalvi J, Deckmyn H, Kotze HF.** Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. *Arterioscler Thromb Vasc Biol.* 2000; 20: 1347-1353.
- Chardin P, Boquet P, Madaule P, Popoff MR, Rubin EJ, Gill DM.** The mammalian G protein rhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilaments in Vero cells. *EMBO J.* 1989;8:1087-1092.
- Clowes MM, Kocher O, Ropraz P, Chaponnier C, Gabbiani G.** Arterial smooth muscle cells in vivo : relationship between actin isoform expression and mitogenesis and their modulation by heparin. *J Cell Biol.* 1998;107:1939-1945.
- Colman RW, Scott CF, Schmaier AH, Wachtfogel YT, Pixley RA, Edmunds LH Jr.** Initiation of blood coagulation at artificial surfaces. *Ann N Y Acad Sci.* 1987;516:253-267.
- Crook D, Davies MJ, Oliver MF.** Relation of plaque lipid composition to the stability of human aortic plaques. *Arterioscler Thromb Vasc Biol.* 1993;17:1337-1345.
- Cruz CP, Eidt J, Drouilhet J, Brown AT, Wang Y, Barnes CS, Moursi MM.** Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. *J Vasc Surg.* 2001;34:724-729.



**CURE: The CURE Investigators.** Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. *N Eng J Med.* 2001;345:494-502.

**Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP Jr, Chauhan MS, Rodriguez O, Kuntz RE.** Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. *Circulation.* 2001;103:1967-1971.

---

D

**Davies MJ, Bland JM, Hartfartner JRW, Angelini A, Thomas AC.** Factors influencing the presence or absence of acute coronary artery thrombi in suffer ischemic death. *Eur Heart J.* 1989;10:203-208.

**Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J.** Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. *Br Heart J.* 1993;69:377-381.

**Davies MJ, Thomas AC.** Plaque fissuring the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. *Br Heart J.* 1985;53:363-373.

**Davies MJ.** Going from immutable to mutable atherosclerotic plaques. *Am J Cardiol.* 2001;88:2F-9F.

**Davies MJ.** Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995 *Circulation.* 1996;94:2013-2020.

**de Belder AJ, MacAllister R, Radomski MW, Moncada S, Vallance PJ.** Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. *Cardiovasc Res.* 1994;28:691-694.

**de Boer OJ, van der Wal AC, Teeling P, Becjer AE.** Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? *Cardiovasc Res.* 1999;41:443-449.

**de Keulenaer GW, Chappell DC, Ishizaka N, Nerem RM, Alexander RW, Griending** Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase. *Circ Res.* 1998;82:1094-1101.

**de Korte CL, Pasterkamp G, van der Steen AF, Woutman HA, Bom N.** Characterization of plaque components with intravascular ultrasound elastography in human femoral and coronary arteries in vitro. *Circulation.* 2000;102:617-623.

**Deckmyn H, Stassen JM, Vreys I, Van Houtte E, Sawyer RT, Vermeylen J.** Calin from *Hirudo medicinalis*, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters. *Blood* 1995; 85: 712-719.

**Dickson BC, Gotlieb AI.** Towards understanding acute destabilization of vulnerable atherosclerotic plaques. *Cardiovasc Pathol.* 2003;12:237-248.

**Doherty PW, Bushberg JT, Lipton MJ, Meares CF, Goodwin DA.** The use of indium-111-labeled leukocytes for abscess detection. *Clin Nucl Med.* 1978;3:108-110.

**Dupuis J, Tardif JC, Cernacck P, Theroux P.** Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol is Ischemia and Functions of the Endothelium) trial. *Circulation.* 1999;99:3227-3233.

---

## E

**Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J.** Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. *J Clin Invest.* 2000;106:483-491.

**Escolar G & Heras M.** Clopidogrel: a selective inhibitor of platelet ADP receptors. *Drugs Today.* 2000;36:187-199.

---

## F

**Falk E, Fernandez-Ortiz A (a).** Role of thrombosis in atherosclerosis and its complications. *Am J Cardiol.* 1995;75:3B-11B.

**Falk E, Shah PK, Fuster V (b).** Coronary plaque rupture. *Circulation.* 1995;92:657-671.

**Falk E.** Plaque rupture with severe pre-existing stenosis precipitates coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. *Br Heart J.* 1983;50:127-134.

**Falk E.** Unstable angina with fatal outcomes: dynamic coronary thrombosis leading to infarction and /or sudden death; autopsy evidence of recurrent mural thrombosis with peripheral embolization culminations in total vascular occlusion. *Circulation.* 1985;71:699-708.

**Fernández-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L.** Characterization of the relative thrombogenicity of



atherosclerotic plaque components: implications for consequences of plaque rupture. *J Am Coll Cardiol*. 1994;23:1562-1569.

**Fihn SD, Williams SV, Daley J, Gibbons RJ.** American College of Cardiology.; American Heart Association.; American College of Physicians-American Society of Internal Medicine.Guidelines for the management of patients with chronic stable angina: treatment. *Ann Intern Med*. 2001; 16;135:616-632.

**Furchgott RF, Zawadzki JV.** The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature*. 1980;288:373-376.

**Fuster V, Badimon JJ, Badimon L (a)** .Clinical-pathological correlations of coronary disease progression and regression. *Circulation*. 1992;86:III1-III11.

**Fuster V, Badimon L, Badimon JJ, Chesebro JH (b).** The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med*. Parts 1 and 2, 1992;326:242-250, 310-318.

**Fuster V, Bowie RJW, Lewis JC, Fass DN, Owen CA Jr, Brown AL.** Resistance to atherosclerosis in pigs with Von-Willebrand's disease. Spontaneous and high-cholesterol diet-induced arteriosclerosis . *J Clin Invest*. 1978;61:722-730.

**Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH.** Atherosclerotic plaque rupture and thrombosis. Evolving concepts. *Circulation*. 1990; 82: II47-59.

## G

**Gally JA, Montague PR, Reeke GN Jr, Edelman GM.** The NO hypothesis: possible effects of a short-lived, rapidly diffusible signal in the development and function of the nervous system. *Proc Natl Acad Sci U S A*. 1990;87:3547-3551.

**Geyer M, Wittinghofer A.** GEFs, GAPs, GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins. *Curr Opin Struct Biol*. 1997;7:786-792.

**Gill S, Majumdar S, Brown NE, Armstrong PW.** Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. *Can J Cardiol*. 1997;13:909-913.

**Gordge MP, Meyer DJ, Hothersall J, Neild GH, Payne NN, Noronha-Dutra A.** Copper chelation-induced reduction of the biological activity of S-nitrosothiols. *Br J Pharmacol*. 1995;114:1083-1089.

**Gould KL, Lipscomb K, Calvert C.** Compensatory changes of the distal coronary vascular bed during progressive coronary constriction. *Circulation*. 1975;51:1085-1094.



- Grybauskas P.** Role of tissue factor in atherothrombosis] *Medicina* (Kaunas). 2003;39:1165-1170.
- Guo LJ, Philippu A.** Effects of arterial blood pressure change on release of GABA in the posterior hypothalamus conscious of freely moving rats] *Yao Xue Xue Bao*. 1994;29:401-405.
- Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM.** Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. *Circulation*. 2003;107:2908-2913.
- 
- Hansson GK.** Immune mechanisms in atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2001;21:1876-1890.
- Hao H, Gabbiani G, Bochaton-Piallant ML.** Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. *Arterioscler Thromb Vasc Biol*. 2003;23:1510-1520.
- Hawker RJ, Hawker LM, Wilkinson AR.** Use of indium-111/oxine to label human platelets. *Lancet*. 1978;2:483.
- Herbert JM, Bernat A, Maffrand JP.** Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat. *Thromb Res*. 1993;71:433-441.
- Hindriks G, Ijsseldijk MJ, Sonnenberg A, Sixma JJ, de Groot PG.** Platelet adhesion to laminin: role of Ca<sup>2+</sup> and Mg<sup>2+</sup> ions, shear rate, and platelet membrane glycoproteins. *Blood*. 1992;79:928-935.
- Hinz B, Schroder H.** Nitrate tolerance is specific for nitric acid esters and its recovery requires an intact protein synthesis. *Biochem Biophys Res Commun*. 1998;252:232-235.
- Hirayama A, Noronha-Dutra AA, Gordge MP, Neild GH, Hothersall JS.** S-nitrosothiols are stored by platelets and released during platelet-neutrophil interactions. *Nitric Oxide*. 1999;3:95-104.
- Hjalmarson A, Gilpin EA, Kjekshus J, Schiemen G, Nicod P, Henning H, Ross J.** Influence of heart rate on mortality after acute myocardial infarction *Am J Cardiol*. 1990;65:547-553.
- Hogg N.** The biochemistry and physiology of S-nitrosothiols. *Annu Rev Pharmacol Toxicol*. 2002;42:585-600.

**Horton DB, Libby P, Schonbeck U.** Ligation of CD40 on vascular smooth muscle cells mediates loss of interstitial collagen via matrix metalloproteinase activity. *Ann N Y Acad Sci.* 2000;947:329-336.

**Houdijk WP, Sakariassen KS, Nievelein PF, Sixma JJ.** Role of Factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagens types I and III. *J Clin Invest* 1985;75:531-540.

**Huizinga EG, Schouten A, Connolly TM, Kroon J, Sixma JJ, Gros P.** The structure of leech anti-platelet protein, an inhibitor of haemostasis. *Acta Crystallogr D Biol Crystallogr.* 2001;57:1071-1078.

---

**I**

**Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G.** Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. *Proc Natl Acad Sci U S A.* 1987;84:9265-9269.

**Ignarro LJ, Kadowitz PJ.** The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. *Annu Rev Pharmacol Toxicol.* 1985;25:171-191.

**Ignarro LJ.** Heme-dependent activation of soluble guanylate cyclase by nitric oxide: regulation of enzyme activity by porphyrins and metalloporphyrins. *Semin Hematol.* 1989;26:63-76.

---

**K**

**Kaartinen M, Penttilä A, Kovanen PT.** Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. *Circulation.* 1994;90:1669-1678.

**Kaartinen M, Penttilä A, Kovanen PT.** Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha. *Circulation.* 1996;94:2787-2792.

**Kaartinen M, van der Wal AC, van der Loos CM, Pick JJ, Koch KT, Becker AE, Kovanen PT.** Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. *J Am Coll Cardiol.* 1998;32:606-612.

**Kachru R, Kaul U.** Management of chronic stable angina pectoris from a sceptic's view point. *J Indian Med Assoc.* 2001 ;99:45-7, 50-3.



- Kalafatis M, Takahashi Y, Girma J-P, Meyer D.** Localization of a collagen-interactive domain of human VWF between amino acids residues Gly 911 and Glu 1365. *Blood*. 1987;70:1577-1583.
- Kaposzta Z, Baskerville PA, Madge D, Fraser S, Martin JF, Markus HS.** L-arginine and S-nitrosoglutathione reduce embolization in humans. *Circulation*. 2001;103:2371-2375.
- Karlberg KE, Torfgard K, Ahlner J, Sylven C.** Dose-dependent effect of intravenous nitroglycerin on platelet aggregation, and correlation with plasma glyceryl dinitrate concentration in healthy men. *Am J Cardiol*. 1992;69:802-805.
- Kleschyov AL, Oelze M, Daiber A, Huang Y, Mollnau H, Schulz E, Sydow K, Fichtischerer B, Mulsch A, Munzel T.** Does nitric oxide mediate the vasodilator activity of nitroglycerin? *Circ Res*. 2003;93:e104-12.
- Koenig W.** Fibrin(ogen) in cardiovascular disease: an update. *Throm Haemost*. 2003;89:601-609.
- Koike T.** Antiphospholipid antibodies in arterial thrombosis. *Ann Med*. 2000;32:27-31.
- Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, Finn AV, Virmani R.** The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. *Curr Opin Cardiol*. 2001;16:285-292.
- Kolodgie FD, Burke AP, Farb A, Weber DK, Kutys R, Wight TN, Virmani R.** Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. *Arterioscler Thromb Vasc Biol*. 2002;22:1642-1648.
- Kragel AH, Reddy SG, Wittes JT, Roberts WC.** Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death. *Circulation*. 1989;80:1747-1756.
- Krumenacker JS, Hanafy KA, Murad F.** Krumenacker JS, Hanafy KA, Murad F. Regulation of nitric oxide and soluble guanylyl cyclase. *Brain Res Bull*. 2004;62:505-515.
- Kukovetz WR, Holzmann S, Romanin C.** Mechanism of vasodilation by nitrates: role of cyclic GMP. *Cardiology*. 1987;74:12-19.

L

- Lam JY, Chesebro JH, Fuster V.** Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: a new antithrombotic role for an old drug. *Circulation*. 1988;78:712-716.
- Lam JY, Chesebro JH, Steele PM, Badimon L, Fuster V.** Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. *Circulation*. 1987;75:243-248.
- Langford EJ, Brown AS, Wainwright RJ, de Belder AJ, Thomas MR, Smith RE, Radomski MW, Martin JF, Moncada S.** Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. *Lancet*. 1994;344:1458-1460
- Langford EJ, Wainwright RJ, Martin JF.** Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. *Arterioscler Thromb Vasc Biol*. 1996;16:51-55.
- Laufs U, Endres M, Liao JK.** Regulation of endothelial NO production by Rho GTPase] *Med Klin*. 1999;94:211-218.
- Laufs U, Liao JK.** Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. *J Biol Chem*. 1998;273:24266-24271.
- Lefer AM and Ma XL.** Cytokines and growth factors in endothelial dysfunction. *Crit Care Med*. 1993;21:S9-14.
- Lesauskaite V, Ivanoviene L, Valanciute A.** Programmed cellular death and atherogenesis: from molecular mechanisms to clinical aspects. *Medicina (Kaunas)*. 2003;39:529-534.
- Lev EI, Hasdai D, Scapa E, Tobar A, Assali A, Lahav J, Battler A, Badimon JJ, Kornowski R.** Administration of eptifibatid to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation. *J Am Coll Cardiol*. 2004;43:966-971.
- Liao JK, Shin WS, Lee WY, Clark SL.** Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. *J Biol Chem*. 1995;270:319-324.
- Llorente-Cortes V, Martinez-Gonzalez J, Badimon L.** Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. *Arterioscler Thromb Vasc Biol*. 1998;18:738-746.
- Llorente-Cortes V, Otero-Vinas M, Hurt-Camejo E, Martinez-Gonzalez J, Badimon L.** Human coronary smooth muscle cells internalize versican-modified LDL



through LDL receptor-related protein and LDL receptors. *Arterioscler Thromb Vasc Biol.* 2002;22:387-393.

## M

**Mackay DJ, Hall A.** Rho GTPases. *J Biol Chem.* 1998 ;273:20685-20688

**Mailhac A, Badimon JJ, Fallon JT, Fernández-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon L.** Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: relative contribution of fibrin(ogen) and platelets. *Circulation.* 1994;90:988-996.

**Marley R, Feelisch M, Holt S, Moore K.** A chemiluminescence-based assay for S-nitrosoalbumin and other plasma S-nitrosothiols. *Free Radic Res.* 2000 ;32:1-9.

**Martinez-Gonzalez J, Raposo B, Rodriguez C, Badimon L.** 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. *Arterioscler Thromb Vasc Biol.* 2001;21:804-809.

**MASS investigators.** Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MASS). *Lancet.* 1994;344:633-638.

**Maurer T, Bonke J, Frech M, Rysiok T, Kañbitzer HB.** Sequential assignment and secondary structure of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen. *J Biomol NMR.* 2001;21:77-8.

**McGhie AI, McNatt J, Ezov N, Cui K, Mower LK, Hagay Y, Buja LM, Garfinkel LI, Gorecki M, Willerson JT.** Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. *Circulation.* 1994;90:2976-2981.

**McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ, Akers DL.** L-arginine inhibits balloon catheter-induced intimal hyperplasia. *Biochem Biophys Res Commun.* 1993;193:291-296.

**Megson IL, Webb DJ.** Nitrate resistance in platelets from patients with stable angina pectoris. *Circulation.* 2000;102:E87

**Mehta SR, Yusuf S, Peters RJ, y cols.** Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet.* 2001;358:527-533.



- Mehta J, Mehta P.** Comparative effects of nitroprusside and nitroglycerin on platelet aggregation in patients with heart failure. *J Cardiovasc Pharmacol.* 1980; 2:25-33.
- Metzler B, Xu Q.** The role of mast cells in atherosclerosis. *Int Arch Allergy Immunol.* 1997;114:10-14.
- Meyer BJ, Badimon JJ, Chesebro JH, Fallon JT, Fuster V, Badimon L.** Dissolution of Mural Thrombus by Specific Thrombin Inhibition with r-Hirudin. Comparison with Heparin and Aspirin. *Circulation.* 1998;97:681-685.
- Michiels C.** Endothelial cell functions. *J Cell Physiol.* 2003;196:430-443.
- MIRACLE: Ahsan CH, Shah A, Ezekowitz M.** Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACLE (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial. *Curr Opin Cardiol.* 2001;16:390-393.
- Mohri H, Ohkubo T.** Single-dose effect of enteric-coated aspirin on platelet function and thromboxane generation in middle-aged men. *Ann Pharmacother.* 1993;27:405-410.
- Moons AH, Levi M, Peters RJ.** Tissue factor and coronary artery disease. *Cardiovasc Res.* 2002;53:313-325.
- Moore S, Freidman RJ, Singal DP, et al.** Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. *Thromb Haemost.* 1976;35:70-81.
- Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT.** Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. *Circulation* 1994;90:775-778.
- Morii N, Teru-uchi T, Tominaga T, Kumagai N, Kozaki S, Ushikubi F, Narumiya S.** A rho gene product in human blood platelets. II. Effects of the ADP-ribosylation by botulinum C3 ADP-ribosyltransferase on platelet aggregation. *J Biol Chem.* 1992;267:20921-20926.
- Moulton KS.** Plaque angiogenesis and atherosclerosis. *Curr Atheroscler Rep.* 2001;3:225-233.
- Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M.** Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. *Thromb Haemost.* 2003;89:783-787.
- Munro R, Jones CP, Sawyer RT.** Calin—a platelet adhesion inhibitor from the saliva of the medicinal leech. *Blood Coagul Fibrinolysis.* 1991;2:179-184.
- Murad F.** Cyclic guanosine monophosphate as a mediator of vasodilation. *J Clin Invest.* 1986;78:1-5.



**Myers PR, Minor RL Jr, Guerra R Jr, Bates JN, Harrison DG.** Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. *Nature*. 1990;345:161-163.

---

**N**

---

**Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M.** Does superoxide underlie the pathogenesis of hypertension? *Proc Natl Acad Sci U S A*. 1991;88:10045-10048.

**Nerem RM, Levesque MJ, Cornhill JF.** Vascular endothelial morphology as an indicator of the pattern of blood flow. *J Biomech Eng*. 1981;103:172-176.

**Newby AC.** Molecular and cell biology of native coronary and vein-graft atherosclerosis: regulation of plaque stability and vessel-wall remodelling by growth factors and cell-extracellular matrix interactions. *Coron Artery Dis*. 1997;8:213-224.

**Nishioka H, Horiuchi H, Tabuchi A et al.** Small GTPase Rho regulates Thrombin-induced platelet aggregation. *Biochemical and Biophysical Research Communications*. 2001;280:970-975.

**Nosratola D.V, Xiu Q.W.** cGMP-Mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. *Hypertension* 1999;34:1237-1241.

---

**O**

---

**Olsson U, Ostergren-Lunden G, Moses J.** Glycosaminoglycan-lipoprotein interaction. *Glycoconj J*. 2001;18:789-797.

**Orford JL, Fasseas P, Melby S, Burger K, Steinhubl SR, Holmes DR, Berger PB.** Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. *Am Heart J*. 2004;147:463-467.

**Osende JJ, Shimbo D, Fuster V, Dubar M, Badimon JJ.** Antithrombotic effects of S 18886, a novel orally active thromboxane A<sub>2</sub> receptor antagonist. *J Thromb Haemost*. 2004;2:492-498.

---

**P**

---

- Palinski W.** New evidence for beneficial effects of statins unrelated to lipid lowering. *Arterioscler Thromb Vasc Biol.* 2001;21:3-5.
- Palmer RM, Ferrige AG, Moncada S.** Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature.* 1987;327:524-526.
- Pareti FI, Fujimura Y, Dent JA, Holland LZ, Zimmerman TS, Ruggeri ZM.** Isolation and characterization of a collagen binding domain in human von Willebrand factor. *J Biol Chem* 1986;261:15310-15315.
- Parmley WW.** Optimum treatment of stable angina pectoris. *Cardiovasc Drugs Ther.* 1998; 12 Suppl 1:105-110
- Patrono C.** Efficacy and safety of aspirin in the long-term management of atherothrombosis. *Haematologica.* 2001;86:19-21.
- Patrono C.** Efficacy and safety of aspirin in the long-term management of atherothrombosis. *Haematologica.* 2001;86:19-21.
- Pawloski JR, Swaminathan RV, Stamler JS.** Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation. *Circulation.* 1998;97:263-267.
- Perutelli P, Mori PG.** The human platelet membrane glycoprotein IIb/IIIa complex: a multi functional adhesion receptor. *Haematologica.* 1992;77:162-168.
- Philipp R, Grech ED.** Interventional pharmacotherapy. *BMJ.* 2003;327:43-46
- Pickett WC, Jesse RL, Cohen P.** Initiation of phospholipase A2 activity in human platelets by the calcium ion ionophore A23187. *Biochim Biophys Acta.* 1976;48:209-213.
- PRISM-PLUS: Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P.** Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. *Circulation.* 2002;105:2361-2366.
- PURSUIT.** Autores no listados. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. *N Engl J Med.* 1998;339:436-443.

---

## R

- Rao RN, Falls DG, Gerrity RG, Sethuraman SN, Thiruvaiyaru DS.** Intimal thickness and layering, and smooth muscle cell phenotypes in aorta of youth. *Pathobiology.* 2000;68:18-28.



**Rassaf T, Kleinbongard P, Preik M, Dejam A, Gharini P, Lauer T, Erckenbrecht J, Duschin A, Schulz R, Heusch G, Feelisch M, Kelm M.** Plasma nitrosothiols contribute to the systemic vasodilator effects of intravenously applied NO: experimental and clinical Study on the fate of NO in human blood. *Circ Res.* 2002;91:470-477.

**Ravn HB, Falk E.** Histopathology of plaque rupture. *Cardiol Clin* 1999;17:263-270.

**Rodriguez C, Martinez-Gonzalez J, Sanchez-Gomez S, Badimon L.** LDL downregulates CYP51 in porcine vascular endothelial cells and in the arterial wall through a sterol regulatory element binding protein-2-dependent mechanism. *Circ Res.* 2001;88:268-274.

**Rodriguez C, Raposo B, Martinez-Gonzalez J, Llorente-Cortes V, Vilahur G, Badimon L.** Modulation of ERG25 expression by LDL in vascular cells. *Cardiovasc Res.* 2003;58:178-85.

**Ross R, Glomset JA.** The pathogenesis of atherosclerosis (first of two parts). *N Engl J Med.* 1976;295:369-77.

**Ross R.** Atherosclerosis is an inflammatory disease. *Am Heart J.* 1999;138:S419-420.

**Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, Zeiher AM, Dimmeler S.** Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. *Circ Res.* 2002;91:837-844.

**Roth GJ, Calverley DC.** Aspirin, platelets, and thrombosis: theory and practice. *Blood.* 1994;83:885-898.

## S

**4S: Scandinavian Simvastatin Survival Study Group.** Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet.* 1994;344:1383-1389.

**Saelman EU, Nieuwenhuis HK, Hese KM, de Groot PG, Heijnen HF, Sage EH, Williams S, McKeown L, Galnick.** Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). *Blood.* 1994;83:1244-1250.

**Sakariassen KS, Bolhuis PA, Sixma JJ.** Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. *Nature.* 1979;279:636-638.



- Savage B, Saldivar E, Ruggeri ZM.** Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. *Cell.* 1996;84:289-297.
- Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM.** Identification and biological activity of the active metabolite of clopidogrel. *Thromb Haemost.* 2000;84:891-896.
- Schaffer LW, Davidson JT, Siegl PK, et al.** Recombinant leech antiplatelet protein prevents collagen-mediated platelet aggregation but not collagen graft thrombosis in baboons. *Arterioscler Thromb.* 1993;13:1593-1601.
- Schorr K.** Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. *Semin Thromb Hemost.* 1997;23:349-356.
- Shah PK.** Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. *Prog Cardiovasc Dis.* 2002;44:357-368.
- Shah PK.** Plaque disruption and thrombosis: Potential role of inflammation and infection. *Cardiol Clin.* 1999;17:271-281.
- Shechter M, Merz CN, Rude RK, Paul Labrador MJ, Meisel SR, Shah PK, Kaul S.** Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease. *Am Heart J.* 2000;140:212-218.
- Sixma JJ, van Zauten GH, Saelman EU, Verkleij M, Lankhof H, Nieuwenhuis HH, de Groot PG.** Platelet adhesion to collagen. *Thromb Haemost.* 1995;74:454-459
- Smith TP, Alshafie TA, Cruz CP, Fan CY, Brown AT, Wang Y, Eidt JF, Moursi MM.** Saratin, an inhibitor of collagen-platelet interaction, decreases venous anastomotic intimal hyperplasia in a canine dialysis access model. *Vasc Endovascular Surg.* 2003;37:259-269.
- Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR, Loscalzo J (a).** Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. *Proc Natl Acad Sci USA.* 1992;89:8087-8091.
- Stamler JS, Singel DJ, Loscalzo J (b).** Biochemistry of nitric oxide and its redox-activated forms. *Science.* 1992;258:1898-1902.
- Stary HC (a).** Lipid and macrophage accumulations in arteries of children and the development of atherosclerosis. *Am J Clin Nutr.* 2000;72:1297S-1306S.
- Stary HC (b).** Natural history and histological classification of atherosclerotic lesions: an update. *Arterioscler Thromb Vasc Biol.* 2000;20:1177-1178.
- Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW.** A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a



report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation*. 1995;92:1355-1374.

**Stefanadis C, Vlachopoulos C, Karayannacos P, Boudoulas H, Stratos C, Filippides T, Agapitos M, Toutouzas P.** Effect of vasa vasorum flow on structure and function of the aorta in experimental animals. *Circulation*. 1995;91:2669-78.

**Steinberg D (a).** A critical look at the evidence for the oxidation of LDL in atherogenesis. *Atherosclerosis*. 1997;131:S5-7.

**Steinhubl SR, Berger PB, Mann JT III, y cols.** Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. *JAMA*. 2002;228:2411-2420.

**Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinka T, Kartsenty G, Giachelly CM.** Smooth muscle cell phenotypic transition associated with calcification. *Circ Res*. 2001;89:1147-1154.

## T

**Thadani U.** Treatment of stable angina. *Curr Opin Cardiol*. 1999; 14:349-58.

**Thakur ML, Segal AW, Louis L, Welch MJ, Hopkins J, Peters TJ.** Indium-111-labeled cellular blood components: mechanism of labeling and intracellular location in human neutrophils. *J Nucl Med*. 1977;18:1022-1026.

**Toschi V, Gallo R, Lettino M, Fallon JT, Gerts SD, Fernández-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ.** Tissue Factor modelates the thrombogenicity of human atherosclerotic plaques. *Circulation*. 1997;95:594-599

**Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA.** Inflammatory and thrombotic mechanisms in coronary atherosclerosis. *Heart*. 2003;89:993-997.

**Turitto VT, Weiss HJ, Baumgartner HR.** Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion. *J Clin Invest*. 1984;74:1730-1741.

**Turitto VT.** Blood viscosity, mass transport, and thrombogenesis. *Prog Hemost Thromb*. 1982;6:139-177.

**Tzeng E, Shears LL 2nd, Robbins PD, Pitt BR, Geller DA, Watkins SC, Simmons RL, Billiar TR.** Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia. *Mol Med*. 1996;2:211-25.

## U

**Uemura S, Fathman CG, Rothbard JB, Cooke JP.** Rapid and efficient vascular transport of arginine polymers inhibits myointimal hyperplasia. *Circulation*. 2000;102:2629-2635.

## V

**Van der Wall AC, Becker AE, van der Loss CM, Das PK.** Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. *Circulation*. 1994;89:36-44.

**Vane JR, Moncada S.** Prostacyclin. *Ciba Found Symp*. 1980;71:79-97.

**Vidal F, Colome C, Martinez-Gonzalez J, Badimon L.** Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. *Eur J Biochem*. 1998 ;252:378-384.

**Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM.** Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler Thromb Vasc Biol*. 2000;20:1262-1275.

**Vodovotz Y, Waksman R, Cook JA, Kim WH, Chan R, Seabron R, Collins SD, Pierre A, Bramwell O, Wink D, Mitchell JB, Leon MB.** S-nitrosoglutathione reduces nonocclusive thrombosis rate following balloon overstretch injury and intracoronary irradiation of porcine coronary arteries. *Int J Radiat Oncol Biol Phys*. 2000;48:1167-1174.

## W

**Wallen NH, Andersson A, Hjemdahl P.** Effects of treatment with oral isosorbide dinitrate on platelet function in vivo; a double blind placebo-controlled study in patients with stable angina pectoris. *Br J Clin Pharmacol*. 1994;38:63-70.

**Walter U.** Physiological role of cGMP and cGMP-dependent protein kinase in the cardiovascular system. *Rev Physiol Biochem Pharmacol*. 1989;113:41-88.



**Watanabee T, Pakala R, Katagiri T, Benedict CR.** Angiotensin II and serotonin potentiate endothelin-1-induced vascular smooth muscle cell proliferation. *J Hypertens* 2001;19:731-739.

**Weiblen BJ, Forstrom L, McCullough J.** Studies of the kinetics of indium-111-labeled granulocytes. *J Lab Clin Med.* 1979;94:246-255.

**Weiss SJ.** Tissue destruction by neutrophils. *N Engl J Med* 1989;320:365-376.

**Werns SW, Rote WE, Davis JH, Guevara T, Lucchesi BR.** Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis. *Am Heart J.* 1994;127:727-37.

**Wierzbicki AS, Poston R, Ferro A.** The lipid and non-lipid effects of statins. *Pharmacol Ther.* 2003;99:95-112.

**WOSCOPS.** Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac Farlane PW, McKillop JH, Packard. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. *N Engl J Med.* 1995;333:2419-2425.

**Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring M, Depraetere H, Kotze HF, Deckmyn H.** Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. *Blood.* 2002;99: 3623-3628.

## Y

**Yang F, Zhao P, She M.** The dynamic change of extracellular matrix in human coronary atherogenesis. *Zhonghua Bing Li Xue Za Zhi.* 1998;27:177-181.

**Yang Y, Loscalzo J.** Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. *Circulation.* 2000;101:2144-2148.

## Z

**Zahger D, Fishbein MC, Garfinkel LI, Shah PK, Forrester JS, Regnstrom J, Yano J, Cercek B.** VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. *Circulation.* 1995;92:1269-1273.